Skip to main content

Durvalumab, Tremelimumab, and Radiation Therapy in Treating Patients with Gynecologic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Trial Status: Active

This phase I trial studies the side effects of durvalumab, tremelimumab, and radiation therapy in treating patients with gynecologic cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving durvalumab, tremelimumab, and radiation therapy may work better in treating patients with gynecologic cancer.

Inclusion Criteria

  • Ability to understand and the willingness to sign a written informed consent document; subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Participants must have histologically or cytologically confirmed endometrial, ovarian (including ovarian, fallopian tube, primary peritoneal), cervical, vaginal, or vulvar cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
  • Participants must have measurable disease that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >= 20 mm with conventional techniques or as >= 10 mm (or >= 15 mm for lymph nodes) with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam; in the expansion cohort, additional measurable/target lesions must be located outside the planned radiation field
  • Patients must have progressive disease following prior therapy; specifically, patients must have progressed on platinum-based chemotherapy
  • At least 21 days must have elapsed from prior therapy (chemotherapy or radiation)
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 60%)
  • Body weight of greater than 30 kg
  • Hemoglobin (Hgb) >= 9 g/dl
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Total bilirubin =< 1.5 x normal institutional limits; this last criterion will not apply to patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia [predominantly unconjugated bilirubin] in the absence of evidence of hemolysis or hepatic pathology), who will be allowed in consultation with their physician
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal
  • Creatinine within normal institutional limits OR creatinine clearance > 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance
  • Patients must have at least one lesion not previously irradiated (and not within a previously irradiated field) for which palliative radiation to the abdomen and/or pelvis is potentially indicated and could be safely delivered at the radiation doses specified in this protocol; this lesion must not be within the central nervous system (CNS) (brain or spinal cord), bone or liver, and must not require urgent or emergent palliative radiation given the timing of radiation specified on this protocol; furthermore, this lesion must be located in the abdomen or pelvis and measure at least 2 cm (minimum dimension) and no greater than 6 cm (maximum dimension); palliative radiotherapy would entail involved-field radiotherapy to a single lesion or region to encompass gross disease; whole-abdomen radiotherapy would not be permitted; patients who received prior vaginal brachytherapy would be permitted to receive palliative pelvic radiation; in the expansion cohort at the maximum tolerated dose (MTD), this lesion must not be the only measurable lesion so that it is possible to determine the response rate outside of the radiation treatment field
  • The effects of durvalumab and tremelimumab on the developing human fetus are unknown; for this reason and because radiation is known to be teratogenic, evidence of post-menopausal status or negative urinary or serum pregnancy test for pre-menopausal patients is required; women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause; the following age-specific requirements apply: * Women < 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy) * Women >= 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced oophorectomy with last menses > 1 year ago, had chemotherapy-induced menopause with > 1-year interval since last menses, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)
  • Women of child-bearing potential who are sexually active with a non-sterilized male partner must agree to use at least 1 method of highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 180 days after the last dose of therapy; highly effective methods of contraception, defined as those that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately

Exclusion Criteria

  • Prior exposure to immune-mediated therapy, including anti-PD-1, anti-PD-L1 (including durvalumab) or anti-CTLA-4 directed therapy (including tremelimumab); therapeutic anticancer vaccines are not included in this category; exposure to other investigational agents may be permitted after discussion with the study principal investigator (PI)
  • Chemotherapy, targeted therapy, biologic or hormonal agents within 3 weeks prior to entering the study
  • Radiation therapy within 3 weeks prior to entering the study
  • Current receipt of any other investigational agents
  • Any unresolved toxicity of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 2, including electrolyte abnormalities, from previous anticancer therapy, with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria * Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician * Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the study physician
  • Patients with untreated brain metastases, spinal cord compression, or leptomeningeal carcinomatosis are excluded from this clinical trial; patients with brain metastases or spinal cord compression previously treated with radiation and/or surgery are allowed if local treatment was > 30 days ago, most recent MRI demonstrates stability or decrease in size of all lesions, and the patient has no current neurologic symptoms related to the metastases and treatment and no requirement for corticosteroids related to the prior treatment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and durvalumab or previous toxicity attributed to durvalumab or other PD-1 or PD-L1 directed therapy that led to drug discontinuation
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension, interstitial lung disease, pneumonitis, active peptic ulcer disease or gastritis, active bleeding diatheses, or serious chronic gastrointestinal conditions associated with diarrhea
  • Pregnant women are excluded from this study because durvalumab and tremelimumab are immune checkpoint inhibitors with the potential for teratogenic or abortifacient effects, as is radiation therapy
  • A nursing mother unwilling to discontinue breastfeeding; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with durvalumab, tremelimumab and radiation, breastfeeding should be discontinued if the mother is treated with durvalumab, tremelimumab and radiation
  • Female patients who are pregnant or breastfeeding or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period
  • Human immunodeficiency virus (HIV)-positive patients are ineligible due to the risks associated with immune checkpoint blockade
  • Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab and tremelimumab; the following are exceptions to this criterion: * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection) * Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent * Steroids as pre-medication for hypersensitivity reactions (e.g., CT scan pre-medication)
  • Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of immunotherapy; Note: Local surgery of isolated lesions for palliative intent is acceptable
  • History of allogeneic organ transplantation
  • Active or prior documented autoimmune or inflammatory disorders; patients without active disease in the last 5 years may be included after consultation with the study physician; this includes: inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis, and diverticulitis with the exception of diverticulosis; sarcoidosis syndrome, or other serious GI chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener syndrome (granulomatosis with polyangiitis); myasthenia gravis; Graves’ disease; rheumatoid arthritis; hypophysitis; or uveitis; the following are exceptions to this criterion: * Vitiligo or alopecia * Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment * Any chronic skin condition that does not require systemic therapy * Celiac disease controlled by diet alone
  • History of another primary malignancy except for: * Malignancy treated with curative intent and with no known active disease >= 5 years before the first dose of study drug and of low potential risk for recurrence * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease (e.g., cervical cancer in situ)
  • Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 consecutive electrocardiograms (EKGs) using Fridericia’s correction at baseline or before dosing
  • History of active primary immunodeficiency
  • Known history of previous clinical diagnosis of tuberculosis
  • Active infection including hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result) or hepatitis C; patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible; patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)
  • Receipt of live attenuated vaccine within 30 days prior to the first dose of investigational treatment; Note: patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of investigational treatment
  • Psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational treatment or interpretation of patient safety or study results


Brigham and Women's Hospital
Status: ACTIVE
Contact: Martin T. King
Phone: 617-732-4332
Dana-Farber Cancer Institute
Status: ACTIVE
Contact: Martin T. King
Phone: 617-732-4332


I. To determine the safety and tolerability of durvalumab and tremelimumab when delivered in combination with radiotherapy to an abdominal and/or pelvic site in patients with recurrent gynecologic cancer.


I. To report the overall response rate (excluding irradiated lesion[s]) using Response Evaluation Criteria in Solid Tumors (RECIST) and immune RECIST (irRC) criteria for durvalumab and tremelimumab in combination with abdominal and/or pelvic radiation.

II. To determine local response rate and local control within the radiation field.

III. To determine the abscopal response rate for measurable disease outside the radiation field.

IV. To estimate 6- and 12-month rates of progression-free and overall survival, as well as response duration.

V. To identify prognostic markers of treatment response by evaluating PD-1 and PD-L1 expression, the presence of tumor infiltrating lymphocytes [TILs], and mismatch repair status.


Patients receive tremelimumab intravenously (IV) over 1 hour on day 1 of cycles 1-4 and durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive radiation therapy for 1-5 days of week 1.

After completion of study treatment, patients are followed up every 8 weeks for 1 year.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Martin T. King

  • Primary ID 17-382
  • Secondary IDs NCI-2018-00221
  • ID NCT03277482